SIGN UP

Matt Kapusta, uniQure CEO

January 31, 2023 10:35 AM EST

UniQure cashes out $10M upfront to get candidate for inherited ALS

Paul Schloesser

Associate Editor

Gene therapy player uniQure has signed a new agreement with Apic Bio for its ALS gene therapy.

The biotech said Tuesday …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

sponsored

Are programs with compounded GLP-1s safe for your population?